RxDoctor Payments Data

Benjo Ysmael Tan

Psychiatric/Mental Health · Santa Ana, CANPI 1841966249

Payments from drug & device makers

$4,432in general payments, 2019–2025

Across 168 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$827
  • Neurocrine Biosciences, Inc.$545
  • Alkermes, Inc.$526
  • Teva Pharmaceuticals USA, Inc.$525
  • Otsuka America Pharmaceutical, Inc.$501
  • Johnson & Johnson$397
  • plus $1K from 7 others

What the payments were for

  • Food & beverage$4,38599%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,432 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$245,069
Medicare patients
551
Services billed
3,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine16$87,001
IngrezzaValbenazine Tosylate12$81,480
Invega SustennaPaliperidone Palmitate24$62,849
Divalproex Sodium153$7,414
Quetiapine Fumarate308$6,257
Risperidone313$5,914
Olanzapine OdtOlanzapine33$5,435
XareltoRivaroxaban13$4,478
Olanzapine97$3,918
Valproic AcidValproic Acid (As Sodium Salt)52$3,370
Aripiprazole65$3,185
Clozapine70$3,180
Duloxetine Hcl27$3,035
Trazodone Hcl166$1,850
Haloperidol Decanoate23$1,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$525$87,00116 claims
Neurocrine Biosciences, Inc.Ingrezza$545$81,48012 claims
Johnson & JohnsonInvega Sustenna, Xarelto$397$67,32737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →